Drugs / HLD-0117
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07524855 | Apr 2026 → Apr 2028 expected | breast cancer | Halda Therapeutics OpCo, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLD-0117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07524855 ↗ |
| Route | Oral | “oral single-agent, HLD-0117” NCT07524855 ↗ |